| Description | NPS2390 is a first generation quinoxaline derivative that acts as a noncompetitive antagonist of mGluR1 and mGluR5 (IC50 of 5.2 and 82 nM, respectively) |
| In vitro | Treatment of NPS2390 was conducive to inhibit the proliferation and reverse phenotypic modulation of PASMCs by regulating autophagy levels. |
| Target activity | mGluR5:82 nM, mGluR1:5.2nM |
| molecular weight | 307.39 |
| Molecular formula | C19H21N3O |
| CAS | 226878-01-9 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 3.07 mg/mL (10 mM), Sonication is recommended. |
| References | 1. Peng X , Wei C , Li H Z , et al. NPS2390, a Selective Calcium-sensing Receptor Antagonist Controls the Phenotypic Modulation of Hypoxic Human Pulmonary Arterial Smooth Muscle Cells by Regulating Autophagy[J]. Journal of Translational Internal Medicine, 2019, 7(2):59-68. |